Clinical Research Directory
Browse clinical research sites, groups, and studies.
Helicobacter Pylori Eradication According to DPO-PCR Methods (K-CREATE) Study)
Sponsor: Incheon St.Mary's Hospital
Summary
Clarithromycin-containing triple therapy is still the primary therapy approved by the Korean government. However, studies of antibiotic resistance have shown that regional resistance patterns to antibiotics such as clarithromycin are increasing. Recent studies show that examining genotype resistance is effective in eradication. Currently, dual priming oligonucleotide-polymerase chain reaction (DPO-PCR) is used to measure clarithromycin resistance. No study has compared the duration of eradication regimens according to DPO-PCR results. This study compares the eradication rate of 7-day triple therapy with 14-day triple therapy in clarithromycin susceptible strains from DPO-PCR. The investigators also aimed to compare the eradication rates of 7-day bismuth quadruple therapy with 14-day bismuth quadruple therapy from clarithromycin-resistant strains from DPO-PCR.
Official title: Helicobacter Pylori Eradication According to DPO-PCR Methods: Duration of Triple Therapy and Bismuth Quadruple According to Clarithromycin Resistance Patterns (K-CREATE Study)
Key Details
Gender
All
Age Range
20 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
1230
Start Date
2021-07-14
Completion Date
2025-03-30
Last Updated
2024-05-16
Healthy Volunteers
Yes
Conditions
Interventions
Duration of eradication regimen
14 day eradication regimen
Locations (1)
Incheon St. Mary's Hospital
Incheon, South Korea